Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease

Abdullah Sarkar; Kailash Prasad; Bulat A. Ziganshin; John A. Elefteriades

doi:10.12945/j.aorta.2013.13-047

AORTA, Inhaltsverzeichnis

CC BY 4.0 · Aorta (Stamford) 2013; 01(03): 210-217
DOI: 10.12945/j.aorta.2013.13-047

Basic Science for the Clinician

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease

Abdullah Sarkar

¹Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut

²College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

,

Kailash Prasad

³Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

,

Bulat A. Ziganshin

¹Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut

⁴Department of Surgical Diseases # 2, Kazan State Medical University, Kazan, Russia

,

John A. Elefteriades

¹Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut

› Institutsangaben

Abstract

Aortic disease has a high rate of morbidity and mortality, and there are no documented screening methods to date. Yet biochemical research does show a significant link between soluble receptor for advanced glycation end-products (sRAGE) protein and cardiovascular disease. Therefore, it can be hypothesized that sRAGE plasma levels may help differentiate patients with aortic disease from the general population, which this paper will review and present.

Key Words

sRAGE - Aortic disease - Aortic aneurysm - Screening biomarker

Volltext

Referenzen

References
1 Control NCfIPa. WISQARS leading causes of death reports, 1999-2007. 2012 [cited 2012 April 10]; Available from: http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html
2 Elefteriades JA. Beating a sudden killer. Sci Am 2005; 293: 64-71 . 10.1038/scientificamerican0805-64
3 Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF. , et al. Diabetic vascular disease: it's all the RAGE. Antioxidants Redox Signaling 2005; 7: 1588-1600 . 10.1089/ars.2005.7.1588
4 Geroldi D, Falcone C, Emanuele E, DAngelo A, Calcagnino M, Buzzi MP. , et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23: 1725-1729 . 10.1097/01.hjh.0000177535.45785.64
5 Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A. , et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4634 . 10.1210/jc.2005-2559
6 Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N. , et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43: 511-518 . 10.1016/j.freeradbiomed.2007.03.015
7 Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E. , et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007; 43: 1255-1262 . 10.1016/j.freeradbiomed.2007.06.017
8 Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P. , et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62: 1734-1736 . 10.1001/archneur.62.11.1734
9 Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A. , et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-2287 . 10.1161/STROKEAHA.107.505354
10 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
11 Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci 2009; 116: 621-637 . 10.1042/CS20080494
12 Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin J, Li H. , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109 . 10.1042/BJ20021371
13 Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL. , et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70-77 . 10.1016/j.atherosclerosis.2005.06.013
14 Bucciarelli LG, Wendt T, Qu W, Lu W, Lalla E, Rong LL. , et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835 . 10.1161/01.CIR.0000039325.03698.36
15 McNair ED, Wells CR, Qureshi AM, Basran R, Pearce C, Orvold J. , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18: 187-192 . 10.1055/s-0031-1278352
16 Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M. , et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-1037 . 10.1161/01.ATV.0000160342.20342.00
17 Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol 2005; 25: 879-882 . 10.1161/01.ATV.0000164804.05324.8b
18 Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes Vasc Dis Res 2009; 6: 7-14 . 10.3132/dvdr.2009.002
19 Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009; 48: 1190-1196 . 10.1093/rheumatology/kep199
20 Thorpe SR, Baynes JW. Millard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25: 275-281 . 10.1007/s00726-003-0017-9
21 Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J. , et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on endothelial cell surface. J Biol Chem 1992; 267: 14987-14997
22 Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb Vasc Biol 1994; 14: 1521-1528 . 10.1161/01.ATV.14.10.1521
23 Ramasamy R, Schmidt AM. Receptor for advance glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 2012; 9: 107-116 . 10.1007/s11897-012-0089-5
24 Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advance glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-40105 . 10.1074/jbc.M006993200
25 Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C. , et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-822 . 10.1161/hc0702.104183
26 Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y. , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901 . 10.1016/S0092-8674(00)80801-6
27 Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003; 52: 2381-2388 . 10.2337/diabetes.52.9.2381
28 Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A. , et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-3727 . 10.1096/fj.08-109033
29 Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 2008; 370: 1-5 . 10.1016/j.bbrc.2008.02.163
30 Zhang F, Kent KC, Yamanouchi D, Zhang Y, Kato K, Tsai S. , et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009; 250: 416-423 . 10.1097/SLA.0b013e3181b14a18
31 Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004; 279: 5059-5065 . 10.1074/jbc.M310124200
32 Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L. , et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutrition Metab Cardiovasc Dis 2009; 19: 129-134 . 10.1016/j.numecd.2008.03.004
33 Qi Y, Gong F, Zhang Q, Xie C, Wang W, Fu S. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease. Arthritis Res Ther 2012; 14: R251 . 10.1186/ar4094
34 Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X. , et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007; 56: 4174-4181 . 10.1002/art.23042
35 Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T. , et al. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 2010; 210: 614-618 . 10.1016/j.atherosclerosis.2009.12.029
36 Park HY, Yun KH, Park DS. Levels of soluble receptor for advanced glycation end products in acute ischemic stroke without a source of cardioembolism. J Clin Neurol 2009; 5: 126-132 . 10.3988/jcn.2009.5.3.126
37 Yokota C, Minematsu K, Tomii Y, Naganuma M, Ito A, Nagasawa H. , et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009; 287: 41-44 . 10.1016/j.jns.2009.09.013
38 McNair ED, Wells CR, Mabood Qureshi A, Basran R, Pearce C, Orvold J. , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33: 678-685 . 10.1002/clc.20815
39 Ziganshin BA, Elefteriades JA. Thoracic aortic diseases. In: Stergiopoulos K, Brown DL. , Eds. The Evidence-Based Cardiology Consult. New York: Springer; 2014. [In Press].
40 Alexander JJ. The pathobiology of aortic aneurysms. J Surg Res 2004; 117: 163-175 . 10.1016/j.jss.2003.11.011
41 El-Hamamsy I, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol 2009; 6: 771-786 . 10.1038/nrcardio.2009.191
42 Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993; 69 (1 Suppl) S30-S37
43 Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS. , et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003; 130: 411-423 . 10.1242/dev.00223
44 Koullias GJ, Korkolis DP, Ravichandran P, Psyrri A, Hatzaras I, Elefteriades JA. Tissue microarray detection of matrix metalloproteinases, in diseased tricuspid and bicuspid aortic valves with or without pathology of the ascending aorta. Eur J Cardio-Thoracic Surg 2004; 26: 1098-1103 . 10.1016/j.ejcts.2004.07.050
45 Della Corte A, Quarto C, Bancone C, Castaldo C, Di Meglio F, Nurzynska D. , et al. Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: focus on cell-matrix signaling. J Thoracic Cardiovasc Surg 2008; 135: 8-18 , 18 e11-12. 10.1016/j.jtcvs.2007.09.009
46 Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C. , et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070-1077 . 10.1161/01.CIR.0000086014.80477.0D
47 Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA. , et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010; 106: 145-154 . 10.1161/CIRCRESAHA.109.209486
48 Ailawadi G, Eliason JL, Upchurch GR. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg 2003; 38: 584-588 . 10.1016/S0741-5214(03)00324-0
49 Zhao L, Moos MP, Gräbner R, Pédrono F, Fan J, Kaiser B. , et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med 2004; 10: 966-973 . 10.1038/nm1099